Paulo Ugarte

Melphalan 100 / m2 is better sometimes

Honored to be able to share our data on outpatient HCT, a feasible and safe strategy @ASTCT #TANDEM26

Discover groundbreaking advancements and engage with experts during the ASTCT Spotlight Sessions at #Tandem26, hosted by ASTCT Committees & SIGs. Visit the online program and filter “ASTCT Spotlight Sessions” to view session details: ow.ly/Ich050Y2888

🇲🇽 Ugarte-Pelaez 489 🔗 Short-Duration Blinatumomab for Residual Disease Eradication as a Bridge to Transplant in B-ALL Innovative, resource-adapted strategy showing high MRD clearance before HCT. #Tandem26 #BMTsm

We offer HCT for all in accordance to our department's mission to offer innovative therapies that are actually affrodable. This has led to an influx of referrals from accross the country and many countries in the continent for #BMTsm to Monterrey 🇲🇽 We are happy but also worried because people are forced to travel great distances and face many challenges, many of which are not medical and hard for us to solve. #Tandem26 @ASTCT @LABMT2

Most patients with ALL in Mexico who undergo HCT are in ≥CR2, ahve not been exposed to blinatumomab or inotuzuamb and were conditioned with non-TBI regimens. There are no CAR-T available. This is the reality for most of Latin America and LMICs #BMTsm #TcellRx #CARTcells #Tandem22 @ASTCT #Leusm

Blinatumomab is effective even if given for <28 days in patients with MRD+ ALL. How long do you actually need it? Surprise! We don’t know. No one knows. In adults we do 7 days based on a Chinese study and it works fine! #Tandem26 #BMTsm #CARTcells

In outpatient transplants patients with good nutritional status have a better experience. Important to assess before. What are the best interventions? #Tandem26 #BMTsm

TMLI 12Gy conditioning is feasible as outpatients we now do this routinely for patients with ALL. Good strategy where TBI is not a good idea if toxicity concerns? We’ll see… #BMTsm #Leusm #Tandem26

TMLI 12Gy is better tolerated than FluMel140, can be done outpatient. #Tandem26 #Leusm #BMTsm

ASH has released new Clinical Practice Guidelines on the diagnosis of light chain (AL) amyloidosis, a rare and life-threatening bone marrow disorder. The guidelines present 12 evidence-based recommendations designed to help clinicians improve diagnosis. ow.ly/OMEV50Y4S71

The countdown is on for #Tandem26! Mark your calendar for my presentation on February 4 and 6 about Outpatient allo-HSCT. I look forward to connecting with you in Salt Lake City! tandemmeetings.com

🔸 From the 70th anniversary special issue #BJHaem70🔸 Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival buff.ly/apDaERq

Did not see that coming: Liberalized diet was not a safe alternative to neutropenic diet in randomized trial of BMT/acute leukemia patients because of increased infection risk without nutritional or other benefit ⁦@JCO_ASCO⁩ ascopubs.org/doi/10.1200/JC…

🇬🇹 at @ASH_hematology #ASH25 @dr_ugarte @GTMedResearch

CRLF2 by flow at diagnosis is associated with a poor prognosis in Mexican children and adults with ALL treated with chemo-transplant. Need more first line immunotherapy #ASH25 #Leusm #BMTsm

as #ASH25 starts, our team is pleased to share the publication of a tour-de-force review on the global epidemiology of #AMLsm published in @Nature Reviews of Clinical Oncology (You can read entire paper free online at rdcu.be/eTiuA @YaleCancer @Yale @YaleHematology

Very effective and well tolerated monotherapy for relapsed / persistent AL Amyloidosis. Performs better than any other known 2nd line Rx. Rates of ASCT in U.S. will continue to decline for AL and do we need to store stem cells anymore. I wonder if time limited (6m) BsAb will be as effective as CAR T (one-time) for AL amyloid. @rajshekharucms #ASH25 #MMSM @ASH_hematology

#ASH25 Are we ready to move to a chemofree approach in 1L in older adults with MCL? Results coming from non-randomized MAVO, TRAVERSE and BOVEN trials. #lymsm

Acalabrutinib-venetoclax-obinutuzumab in MCL. Can't wait for a phase 3 trial comparing chemo-free triplets to soc ict regimens. #ASH25